Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

2021

Slider News

2021

  • 2021 - 01 - 21

    Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • 2021 - 01 - 22

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day

  • 2021 - 03 - 08

    Press Release March 5th

  • 2021 - 03 - 29

    Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS<sup>®</sup> (Tagraxofusp) in Japan

  • 2021 - 04 - 08

    INTERNATIONAL FAIR PLAY-MENARINI AWARDS TO CELEBRATE 25-YEAR ANNIVERSARY

  • 2021 - 04 - 09

    Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers

  • 2021 - 04 - 16

    Covid-19: Menarini, new reagent made in Italy for the isolation of viral RNA

  • 2021 - 05 - 14

    Menarini receives the coveted M&A Award 2021 for the 2020 acquisition of US company Stemline Therapeutics

  • 2021 - 05 - 24

    Le Volpi Rosse Menarini Campioni d'Italia: La squadra giovanile conquista il suo primo, storico, scudetto

  • 2021 - 05 - 28

    Menarini Silicon Biosystems launches new breakthrough DEPArray™ PLUS image-based cell sorter to isolate rare cells with single cell precision

  • 2021 - 06 - 01

    Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial

  • 2021 - 06 - 09

    Press Release June 10th

  • 2021 - 06 - 11

    The “youth Role model” category of the Fair Play - Menarini Award named in memory of champion footballer Paolo Rossi

  • 2021 - 07 - 15

    International Fair Play Menarini Award: programme and names of the winners of the xxv edition revealed

  • 2021 - 09 - 02

    Sporting legends shine on a magical evening at the Menarini Fair Play awards

  • 2021 - 10 - 12

    Antibiotic-resistance: Welcome to the "Infection in Focus" website

  • 2021 - 10 - 19

    Serie A: the Volpi Rosse Menarini are ready to meet the challenge

  • 2021 - 10 - 20

    Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

  • 2021 - 11 - 04

    Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

  • 2021 - 11 - 30

    New CELLSEARCH<sup>®</sup> Circulating Multiple Myeloma Test now available to help community physicians optimize patient care

  • 2021 - 12 - 08

    Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

  • 2021 - 12 - 13

    Menarini: a gift to the Misericordia Campo di Marte to give life to their new ‘home’

  • 2021 - 12 - 14

    Menarini Silicon Biosystems Announces study results to be presented at American Society of Hematology (ASH) Annual Meeting

  • 2021 - 12 - 16

    Menarini Silicon Biosystems announces new DEPArray™ PLUS application to identify mutations in FFPE tissue samples with low tumor cellularity

  • 2021 - 12 - 21

    Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO<sup>®</sup> (selinexor) in Europe and Other Key Global Territories

  • 2021 - 12 - 22

    Pope Francis welcomes in audience the Fair Play Menarini Award